

Edgar Filing: ANIKA THERAPEUTICS INC - Form 8-K

ANIKA THERAPEUTICS INC  
Form 8-K  
June 11, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported) June 5, 2009

-----  
Anika Therapeutics, Inc.

-----  
(Exact Name of Registrant as Specified in Its Charter)

-----  
Massachusetts

-----  
(State or Other Jurisdiction of Incorporation)

000-21326

04-3145961

-----  
(Commission File Number)

(IRS Employer Identification No.)

32 Wiggins Avenue, Bedford, Massachusetts

01730

-----  
(Address of Principal Executive Offices)

(Zip Code)

(781) 457-9000

-----  
(Registrant's Telephone Number, Including Area Code)

-----  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Edgar Filing: ANIKA THERAPEUTICS INC - Form 8-K

(e) Amendment and Restatement of Stock Option Plan.

As previously disclosed, on May 29, 2009, the Board of Directors of Anika Therapeutics, Inc. (the "Company"), approved an amendment to the Company's Amended and Restated 2003 Stock Option and Incentive Plan (the "2003 Plan") to reduce the proposed increase in the number of shares subject to the 2003 Plan from 1,000,000 to 850,000, which would result in a total of 2,350,000 shares of common stock being reserved for issuance under the 2003 Plan.

On June 5, 2009, the Company held its annual meeting of stockholders and based on the certified results, the Company's stockholders approved the 2003 Plan.

A copy of the 2003 Plan, reflecting the 2,350,000 shares of common stock reserved for issuance, is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

10.1 Anika Therapeutics, Inc. Amended and Restated 2003 Stock Option and Incentive Plan

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANIKA THERAPEUTICS, INC.

Date: June 11, 2009

By: /s/ Kevin W. Quinlan

-----  
Kevin W. Quinlan  
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
10.1	Anika Therapeutics, Inc. Amended and Restated 2003 Stock Option and Incentive Plan